Introduction
============

It is currently estimated that 5-10% of all breast cancers are hereditary and attributable to mutations in several highly penetrant susceptibility genes, of which only two have been identified: *BRCA1*(OMIM 113705) \[[@B1]\] and *BRCA2*(OMIM 600185) \[[@B2]\]. Earlier estimates suggested that *BRCA1*and *BRCA2*mutations were responsible for 75% of site-specific breast cancer families and the majority of breast and ovarian cancer families \[[@B3],[@B4]\]. Recent data shows however that these percentages may have been overestimated and that the proportion of families classified due to mutations in *BRCA1*or *BRCA2*is much lower and strongly depends on the population analyzed \[[@B5]\] and the specific characteristics of the selected families \[[@B6],[@B7]\]. In fact, the percentage of high risk families associated with mutations in these genes is very similar (around 25%) in all series, including the one we have found in Spain \[[@B8],[@B9]\].

Genetic testing for *BRCA1*and *BRCA2*is expensive and time-consuming due to the large size of both genes, the absence of hot spots for mutations throughout their entire coding regions, and the low percentage of mutated cases. It is therefore important to find clinical or pathological factors that could suggest or exclude the presence of *BRCA1*or *BRCA2*mutations in a given patient.

The histopathology of *BRCA*-associated cancer has been studied by different groups; however the larger series are those reported by the Breast Cancer Linkage Consortium (BCLC) \[[@B10]-[@B12]\]. These studies have demonstrated that cancer arising in carriers of mutations in either the *BRCA1*or *BRCA2*genes differs morphologically from sporadic breast cancers from age-matched controls \[[@B11]-[@B14]\]. In addition, numerous immunohistochemical studies have tried to better characterize the differences between hereditary and sporadic tumours \[[@B10],[@B15]-[@B18]\]. More recently, some reports have also described the pathology of hereditary breast cancer not attributable to *BRCA1*or *BRCA2*germline mutations. The purpose of this review is to present the histopathological characteristic of different genotypes of hereditary breast cancer. Special attention will be given to those characteristics that possibly impact on genetic testing, prognosis and treatment.

Histopathology of BRCA1 and BRCA2 breast cancer
===============================================

In order to better understand the specific characteristics of hereditary breast cancer, the histopathological and immunohistochemical variables usually evaluated in sporadic breast cancer are also presented, since invasive breast carcinoma is a heterogeneous group of malignant epithelial tumours with a wide range of morphological phenotypes and specific histopathological types.

Histological type
-----------------

Invasive ductal carcinoma (IDC) not otherwise specified (NOS) is the most common histological type among sporadic breast cancer, comprising 70-80% of all cases. The most frequent special histological types are invasive lobular carcinoma (5-15%), tubular carcinoma (2%), invasive cribriform carcinoma (0.8-3.5%), medullary carcinoma (1-7%), mucin producing carcinoma (2%), neuroendocrine tumours (2-5%), invasive micropapillar carcinoma (2%). Differences between series are related with the specific population studied or, more probably, with stringency in the application of diagnostic criteria.

Medullary carcinoma is a particular type of carcinoma characterized by the presence of solid sheets of large and pleomorphic cells with indistinct cell borders that lead to a syncytial appearance \[[@B19]\]. They are high-grade tumours with numerous mitosis, and sparse necrosis (\<25%). The border of the tumour is well defined with a pushing edge. The stroma is a dense lymphocytic infiltrate. Despite being a high-grade tumour, it has been associated with a relatively favourable prognosis \[[@B19]-[@B21]\]. Atypical medullary carcinoma is diagnosed when more than 25% of tumour is not classical medullary or the lymphoid infiltration is moderate or the circumscription is not complete.

IDC NOS is the most common histological type in all forms of hereditary breast cancer and it seems to be significantly more frequent in *BRCA1*and *BRCA2*mutation carriers than in non-carriers \[[@B22]\]. In addition, *BRCA1*mutation carriers have a higher incidence of medullary carcinoma (13%) than *BRCA2*mutation carriers (3%) and non-carriers (2%) \[[@B12]\]. When only IDC cases are compared, after excluding medullary carcinomas, *BRCA1*tumours have more frequently a prominent lymphocytic infiltrate and pushing margins \[[@B11]\], some of the features that define the medullary histotype.

Regarding *BRCA2*carcinomas, Marcus et al have reported a higher incidence of *BRCA2*tumours belonging to a \"tubular lobular group\", including invasive lobular, tubular and cribriform carcinomas \[[@B23],[@B24]\]. Armes et al found that *BRCA2*mutation carriers showed an excess of pleomorphic lobular and intraductal carcinomas \[[@B13]\]. However, other series have not found any statistically significant difference in the histological type of *BRCA2*with respect to controls \[[@B11],[@B12],[@B25]\].

Histological grade
------------------

Breast carcinomas are routinely graded based on an assessment of tubule formation, nuclear pleomorphism and mitotic counts. This method of tumour graduation consists of scoring 1-3 for each factor. The grade is obtained by adding the three previous parameters and classifying the tumour as grade 1 (well differentiated or low-grade), grade 2 (moderately differentiated or intermediate-grade) and grade 3 (poorly differentiated or high-grade). This grading system has prognostic implications and the utility has been convincingly proved \[[@B26],[@B27]\].

BRCA1 tumours are more frequently high-grade (grade 3) tumours because they show less tubule formation, higher pleomorphism and a higher number of mitosis than sporadic age-matched breast cancer controls. Thus, the reported incidence of grade 3 tumours in BRCA1 mutation carriers ranged from 66% to 84% in different studies \[[@B12],[@B28],[@B29]\] while the proportion of grade 3 tumours in sporadic age-matched breast cancer controls was between 30% and 40% \[[@B12],[@B28],[@B29]\].

BRCA2 tumours tend to be of higher grade than sporadic controls, although this association is less strong than for BRCA1 cases. Most BRCA2 tumours are grade 2/3, and show less tubule formation but similar cellular pleomorphism and mitotic count than sporadic cases \[[@B12]\]. Furthermore this difference in tubule formation, Agnarsson et al \[[@B25]\] have reported more nuclear pleomorphism and higher mitotic rates in BRCA2 tumours than in sporadic tumours.

Hormone receptors and associated markers
----------------------------------------

Sporadic breast cancer tumours express a number of immunohistochemical markers that provide prognostic and predictive information about these tumours. In this sense, approximately 70% of breast carcinomas express the oestrogen receptor (ER) protein and 50% are progesterone receptor- (PR) positive. ER-positive tumours are more frequently well or moderately differentiated, p53- and HER2-negative and have a lower proliferation rate and better overall survival, but do not have a lower metastatic potential. ER-positive and PR-positive tumours respond to anti-oestrogen treatment in approximately 75% of the cases. The response is 34% when the tumour is ER-positive and PR-negative, and 45% in the case of ER-negative and PR-positive tumours. Only a small proportion of ER-negative and PR-negative (\<10%) respond to anti-oestrogens, perhaps reflecting false negative ER measurement \[[@B30]\].

Many authors have emphasized the high frequency of ER-negativity in BRCA1 tumours, \[[@B10],[@B18],[@B28],[@B29],[@B31]-[@B34]\]. Between 73% and 90% \[[@B28],[@B29],[@B31]\] of BRCA1 carcinomas have been reported to be ER-negative in different series. Although it has been suggested that this relationship might be explained by the higher grade of tumours and younger age of patients, BRCA1 tumours are more likely ER-negative than sporadic ones, when tumours from patients at the same age are compared. In addition, the likelihood of ER-negativity is 4.8 times higher in BRCA1 grade 3 tumours when they are compared with grade 3 sporadic cases \[[@B18]\]. In this sense, for example, Lakhani et al \[[@B10]\] reported that 90% of BRCA1-related breast cancers were ER-negative compared with 35% in controls.

PR expression in BRCA1 tumours is also lower than in sporadic tumours. In the study of Lakhani et al \[[@B10]\] 79% of BRCA1 tumours were PR-negative compared with 41% in sporadic tumours. The same proportion has been observed in other publications \[[@B28],[@B29],[@B31]\].

In contrast to BRCA1 tumours, those arising in BRCA2 mutation carriers do not differ from controls with regard to ER and PR expression. Thus, ER expression has been reported in around 65% of BRCA2 tumours \[[@B10],[@B31],[@B32]\]. Between 40% and 60% of BRCA2 carcinomas expressed PR \[[@B10],[@B31],[@B32]\].

Taking into account the differences in hormone receptor status between BRCA1 and BRCA2 tumours, it is not surprising that the expression of some markers is consistently associated with hormone receptors in breast cancer, such as Bcl-2 and cyclin D1, and differ between both genotypes. Bcl-2 is a protein that inhibits programmed cell death (apoptosis). This protein is detected in 50-90% of IDC of the breast \[[@B35],[@B36]\]. Bcl-2 expression is associated with favourable clinicopathological features \[[@B37]\]. Thus, it is more frequently present in well-differentiated ER-positive breast carcinomas. Bcl-2-positive p53-negative tumours have a better response to hormonal therapy than bcl-2-negative p53-positive ones \[[@B35]\]. Bcl-2 has a low rate of expression in BRCA1-associated tumours (31%) with respect to sporadic carcinomas \[[@B28],[@B38]\], but there are no statistically significant differences between BRCA2 and sporadic tumours \[[@B38]\].

Cyclin D1 plays an important role in cell cycle progression during G1 phase. Cyclin D1 is considered a potential oncogene and is amplified in about 15% of IDCs \[[@B39]\]. Cyclin D1 is known to be upregulated by oestrogen and progesterone and to be downregulated by anti-oestrogens \[[@B40]\]. The cyclin D1 protein is detected in 50% of cases \[[@B41]\] and its expression is associated with low histological grade, ER positivity and good prognosis. Several series have detected lower cyclin D1 expression levels in BRCA1 (5% and 33%) than in sporadic tumours \[[@B31],[@B33],[@B42]\]. Cyclin D1 expression in BRCA2 tumours has been found at an intermediate level between BRCA1 and sporadic tumours. Osin et al \[[@B33]\] reported that 27% of BRCA2 tumours expressed cyclin D1 compared with 5% in BRCA1 tumours, and 35% in sporadic tumours. In the same way, Armes et al \[[@B31]\] has shown cyclin D1 positivity in 55% of BRCA2, 33% of BRCA1 and 100% of sporadic tumours.

p53 expression and gene mutations
---------------------------------

Around 15% to 30% of sporadic breast carcinomas have mutations in the tumour suppressor gene *p53*. Most of them are missense mutations that result in the accumulation of stable p53 protein that can be visualized by immunohistochemistry. However, 20% of the mutations do not yield a stable protein and it is not detected by immunostaining. For this reason, a stronger association between clinicopathological variables and p53 mutations, detected by DNA sequencing has been shown rather than with p53 immunohistochemistry detection in breast cancer.

Several studies have demonstrated a high incidence of p53 immunostaining in *BRCA1*when compared to sporadic cases. p53 over-expression has been detected in 45% to 77% of BRCA1-associated tumours \[[@B10],[@B28],[@B29],[@B43],[@B44]\]. The results in *BRCA2*tumours are inconclusive \[[@B10]\]. Some studies have found p53 over-expression in around 50% of BRCA2 carcinomas, whereas in other series the percentage was lower than 20% \[[@B28]\].

The importance of p53 inactivation in *BRCA*-associated tumours is also supported by genetic studies demonstrating a higher frequency and unusual location of *p53*mutations in this group when compared with sporadic cases \[[@B43]-[@B45]\]. In a review of reported cases by Chappuis et al \[[@B22]\] around 40% of BRCA1 and 30% of BRCA2 carcinomas had p53 mutations whereas it was found in only about 20% of sporadic controls. When comparing the spectrum of p53 mutations in BRCA1/2 patients with those reported in the IARC p53 mutation database, Greenblatt et al \[[@B46]\] found that they differed significantly both in distribution and in base changes. Mutations at A:T bp were common in BRCA1/2-associated tumours. Changes were frequent at p53 codons that are not mutation hotspots and were located at the opposite side of the p53 DNA-binding site.

HER2 expression and gene amplification
--------------------------------------

HER2 is the human epidermal growth factor receptor-2 that encodes a transmembrane glycoprotein with intrinsic tyrosine kinase activity. *HER2*gene is located in chromosome 17q12 and has been associated with poor outcome and poor response to anti-oestrogens, but a better response to anthracyclines. Over-expression of HER-2 is identified in 10% to 34% of primary breast tumours \[[@B47],[@B48]\] and is attributable to gene amplification in approximately 90% of cases \[[@B49],[@B50]\]. The humanized anti-HER-2 monoclonal antibody, Herceptin, has been shown to be effective in 20% of patients with HER-2 amplification.

Data regarding HER2 expression in BRCA-associated tumours vary among series, probably indicating technical issues. For example, Armes et al \[[@B31]\] have shown no differences in strong expression of HER-2 between BRCA2 and sporadic breast tumours, 44% and 45% respectively, but they did not find HER-2 expression in any BRCA1 tumours. However, subsequent studies have observed HER2 over-expression in up to 3% in both BRCA1 and BRCA2 tumours \[[@B10],[@B28],[@B51]\]. With regard to the HER-2 amplification, only two studies have analyzed gene status by FISH in hereditary *BRCA1*-associated carcinomas \[[@B28],[@B52]\], and only one in *BRCA2*-associated carcinomas. According to immunohistochemistry data, high level of *HER-2*amplification (\>2.4 copies) has not been reported in BRCA1 and BRCA2 tumours.

BRCA1 carcinomas and the basal cell phenotype
---------------------------------------------

Sorlie et al \[[@B53],[@B54]\] using cDNA microarrays classified breast tumours into clinically relevant subgroups. They defined different subtypes of breast tumours, including two non-overlapping groups of ER-negative carcinomas: the basal like and the ERBB2 over-expressing groups. The basal cell phenotype is characterized by the expression of markers that are usually expressed by the basal or myoepithelial cells of the normal breast. The group of myoepithelial/basal markers include the basal epithelial keratins (CK) 5/6, 14, and 17, muscle-specific actin, P-cadherin, S100, CD10, caldesmon, calponin, EGFR etc. \[[@B55]-[@B57]\]. The existence of a group of breast carcinomas with a basal cell phenotype has been confirmed by other groups using DNA microarray and immunohistochemical approaches \[[@B58]-[@B60]\]. Some of these studies have also indicated the poor prognosis of this group of neoplasias \[[@B17],[@B55],[@B56]\].

Recently Sorlie et al \[[@B53]\] reanalyzing cDNA microarray data from van\'t Veer et al \[[@B61]\], that included 18 BRCA1 and 2 BRCA2 carcinomas, observed that 80% of *BRCA1*carcinomas had a basal epithelial type gene expression profile. Subsequently, Foulkes et al and Palacios et al have found a high prevalence of tumours with a basal phenotype among BRCA1 mutation carriers. For example, Palacios et al \[[@B60]\] reported that CK 5/6 was expressed in 50% of BRCA1 tumours but in less than 10% of BRCA2 cases and sporadic controls. In addition this phenotype is characterized by ER and HER2 negativity and the expression of specific cell cycle markers, such as over-expression of cyclin E and down-regulation of p27. Interestingly, a high proportion (60%) of BRCA1 carcinomas have been reported to over-express EGFR \[[@B10],[@B16],[@B57],[@B60],[@B62]\].

Histopathology of familial non-BRCA1/2 tumours
==============================================

There are two studies that have defined the histological characteristics of these neoplasias \[[@B28],[@B63]\]. This group of tumours represents 67% of familial breast cancer when families with only female breast cancer and 4-5 affected members are considered \[[@B6]\]. In the Spanish population, when considering families with at least three cases of female breast cancer and one of them \<50 years, the percentage of cases non-attributable to BRCA1/2 mutation was 75% \[[@B8]\].

IDC is the most frequent histological type in familial non-BRCA1/2: 77% of the cases according to Lakhani et al \[[@B63]\] and 78% in the series by Palacios et al \[[@B28]\]. An excess of lobular carcinomas was found in familial non-BRCA1/2 (15%) when compared with BRCA1 (3%), BRCA2 (9%) and sporadic cases (10%). The difference was only significant with respect to BRCA1 tumours \[[@B63]\].

Breast cancers from familial non-BRCA1/2 patients were of lesser histological grade than BRCA1/2-associated tumours \[[@B28],[@B63]\]. Thus, grade 1 tumours accounted for 27% to 50% in total. In addition, non-BRCA1/2 tumours showed more tubule formation, a lower mitotic index and lesser pleomorphism than BRCA1/2-associated carcinomas \[[@B28],[@B63]\].

In the only immunohistochemical study in familial non-BRCA1/2 \[[@B28]\], these tumours were more frequently ER- (75%), PR- (67%), and BCL2-positive (55%), but p53-negative (3.7%); these figures clearly differed from BRCA1 tumours, but no significant differences were found with respect to BRCA2 carcinomas. A low incidence of HER2 expression and amplification (4%) was found in non-BRCA1/2 carcinomas \[[@B28]\].

Pathology findings in prophylactic mastectomy specimens from BRCA1/2 mutation carriers
======================================================================================

The natural history of hereditary breast cancer from morphologically normal epithelium to invasive disease is not well understood. The incidence of in situ lesions associated with invasive carcinomas is poorly described in most publications. Overall, an in situ component is less common around IDC in BRCA1 mutation carriers than in controls \[[@B12]\]. In addition, the incidence of in situ lesions in the absence of an invasive component in familial breast cancer is not established.

The study of prophylactic mastectomy specimens from BRCA1/2 mutation carriers has been proposed as a means to better understand the different stages of breast cancer development in these patients. However, the lack of data available is not conclusive due to the low number of case studies and the difficulty in selecting appropriate controls which is confounded by difficulties in recognizing precursor lesions.

Hoogerbrugge et al have reported a study with 67 patients at high risk of breast cancer, 44 of them with BRCA mutation, who underwent unilateral or bilateral prophylactic mastectomy. One or more different types of high-risk precursor lesions were present in 57% of the women: 37% had atypical lobular hyperplasia (ALH), 39% atypical ductal hyperplasia (ADH), 25% lobular carcinoma in situ (LCIS), and 15% ductal carcinoma in situ (DCIS). A 4-mm invasive ductal carcinoma was found in one woman with ductal carcinoma in situ. Prior to mastectomy, palpation or mammography was performed and none of these lesions were detected. These high risk lesions were more frequent in the group of women aged 40 years and older (73% vs. 43%) and less frequent in BRCA mutation carriers (43%) and women who had undergone bilateral oophorectomy before prophylactic mastectomy (20%) \[[@B64]\].

In another study, Kauff et al \[[@B65]\] compared prophylactic mastectomy specimens from 24 women with BRCA mutations and 48 controls extracted from an autopsy registry, concluding that BRCA mutation carriers have a higher incidence of high risk lesions including DCIS, LCIS, ADH or ALH (46%) compared to control cases (6%).

Adem et al \[[@B66]\] compared prophylactic mastectomy from patients with a family history of breast cancer including 28 BRCA1/2 mutation carriers, 117 women without BRCA1/2 mutation, 12 unclassified mutation variant carriers, and 283 sporadic control cases. They found similar prevalence of DCIS in all groups 53%, 60%, 56%, 55%, respectively. However, in BRCA1/2 mutation carriers, the prevalence of proliferative fibrocystic changes was lower (7%) compared with 25% in sporadic cases. In contrast, the proportion of invasive carcinomas was higher in mutation and unclassified variant alteration carriers compared with the control group and the mutation negative group, suggesting a faster progression of precursor lesions in mutation carriers.

Genetic testing and therapeutic implications
============================================

Available data concerning morphological and immunohistochemical characteristics of hereditary breast cancer demonstrated major differences between genotypes. The most important differences were found between tumours in BRCA1 carriers and all other categories. These histopathological features in conjunction with clinical data can be used to predict BRCA1 status and to a lesser extent BRCA2 and non-BRCA1/2 status and this could have implications for the process of mutation screening.

In this sense, it has been suggested that the immunohistochemical analysis of ER, together with age and histological grade, provides a new powerful predictor of *BRCA1*mutation status. It has been estimated that the probability of a woman with familial breast cancer diagnosed before 35 years to be a *BRCA1*mutation carrier is 25% if the tumour is grade 3 and ER-negative but the probability is only 5% if the tumour is ER-positive \[[@B10]\]. Taken into account the high proportion of BRCA1 carcinomas that express basal markers (i.e. CK 5/6), it is likely that the addition of such markers in the pathological study will improve our ability to predict the BRCA1 genotype.

Alternatively, if we have a tumour which is high grade (grade 2-3), ER-, and PR-positive and CK5/6-negative in a family with more than six female breast cancers in the first and second generations, early-onset prostate cancer or male breast cancer, it is likely we are dealing with a BRCA2 tumour.

Finally, it is very rare to find a BRCA1 or BRCA2 mutation when we are confronted with a low grade tumour (grade 1) with high tubule formation, ER- and PR-positive and p53-negative and a very low proliferation index. The probability of being a non-BRCA1/2 tumour increases if there are between three and six female breast cancer cases in the family, without ovarian cancer or early onset prostate cancer. In such a situation, probably it would be sufficient to study only the more recurrent mutations in each population in order to reduce the possibility of leaving atypical positive cases without diagnosis.

From a therapeutic point of view, adjuvant hormone therapy is not indicated in most BRCA1 tumours, since they are ER- and PR-negative, but can be used in most BRCA2 and non-BRCA1/2 carcinomas. The use of hormone therapy as chemopreventive drugs in BRCA1 patients is debatable \[[@B18],[@B32],[@B67]-[@B70]\]. Taking into account the low incidence of HER2 amplification/over-expression in most hereditary breast cancer, these tumours are not good candidates for treatment with Herceptin. However, the high incidence of EGFR recently reported in BRCA1 tumour \[[@B62]\] opens the possibility that these women can be treated with specific compounds, such as tyrosine kinase inhibitors or anti-EGFR monoclonal antibodies.

###### 

Morphological and immunohistochemical profiles associated with hereditary breast cancer tumours

                    GRADE   RE   RP   BCL2   P53   Ki-67   Cyclin D1   CK5/6
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